1. At a Glance – The Chemical King Who Suddenly Forgot His Own Formula
There are companies that grow slowly…
There are companies that explode like Diwali rockets…
And then there is Paushak Ltd — a company that literally deals with phosgene (yes, the same chemical that sounds like a villain in a war movie)… but somehow manages to deliver quarterly results like a confused student who studied everything except the exam syllabus.
Here’s the drama:
Revenue? Flat-ish.
Profit? Down like your crypto portfolio after Elon tweets something random.
Margins? Still strong, like that one gym guy who skips leg day but has massive arms.
In Q3 FY26, Paushak reported:
- Sales: ₹48.8 Cr
- PAT: ₹6.17 Cr
- Profit YoY crash: -59.6%
Let that sink in.
A specialty chemical company… with strong margins… backed by Alembic group… suddenly shows profit collapse.
It’s like Virat Kohli getting out on a full toss — technically possible, but emotionally unacceptable.
But here’s the twist…
The company just completed:
- ₹175 Cr multipurpose plant commissioning
- ₹250 Cr capex pipeline
- Expansion into semi-specialty chemicals
So the question is:
👉 Is this a temporary digestion problem after capex binge?
👉 Or is the business slowly becoming “mid-cap disappointment chemicals”?
Because right now, Paushak feels like that IIT topper who suddenly scored 55% — not because he forgot everything, but because something deeper is going on.
2. Introduction – The Rise, The Plateau, and The “Abey Kya Ho Raha Hai?” Phase
Paushak isn’t some random chemical startup mixing acids in a garage.
This is:
- Part of the Alembic Group (since 1907 heritage)
- One of the few licensed phosgene manufacturers in India
- A niche player in high-entry-barrier chemistry
Basically, entry barrier itna high hai ki normal companies gate pe hi gir jaati hain.
And yet…
Despite this moat, Paushak has:
- 5-year sales growth: just ~8.87%
- Profit growth stagnating
- Stock down ~60% in 6 months
Yes. SIXTY PERCENT.
That’s not correction. That’s emotional damage.
So what went wrong?
CRISIL gives us clues:
- Chinese pricing pressure
- Weak product mix
- Demand fluctuations
- Capex delays
Basically, everything except “management forgot the password to factory.”
But here’s where it gets interesting:
- Margins still ~28% range
- Debt still low
- Parent support strong
So this is not a dying business.
This is a temporarily confused business with expensive ambitions.
Now tell me honestly:
👉 Would you trust a company that is investing heavily while profits are falling?
👉 Or would you run faster than investors ran from Yes Bank?
3. Business Model – WTF Do They Even Do?
Let’s simplify this before your brain melts.
Paushak makes phosgene-based specialty chemicals.
Translation:
They make ingredients that go into:
- Pharmaceuticals
- Agrochemicals
- Dyes
- Plastics
- Perfumeries
Basically, they don’t make the final product…
They make the “secret masala” inside the product.
Think of it like:
👉 Maggi doesn’t sell masala suppliers on TV
👉 But without masala, Maggi = sadness
That’s Paushak.
Their product basket includes:
- Chloroformates
- Isocyanates
- Carbonates
